News

HDA Media And Political Bulletin – 19 July 2016

George Freeman promoted, leaving Life Science minister role in doubt

18 July, Pharmaphorum, Andrew McConaghie

 

George Freeman is to become chair of the Prime Minister’s policy board as part of an extensive reshuffle by Theresa May, recently appointed to the role. It appears that his previous position of Life Science minister will be scrapped and its associated responsibilities moved to the Department of Health and the Department of Business, Innovation and Skills.

 

Philip Dunne appointed to health department

19 July, Dispensing Doctors Association, Ailsa Colquhoun

 

Philip Dunne has been announced as the new Health Minister in the Cabinet reshuffle following the appointment of Theresa May as Prime Minister. This is his first appointment in the Health Department and it is yet unclear if his portfolio will include pharmaceutical services.

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

George Freeman promoted, leaving Life Science minister role in doubt

18 July, Pharmaphorum, Andrew McConaghie

 

George Freeman is to become chair of the prime minister’s policy board, part of an extensive reshuffle by new PM Theresa May.

The Conservative MP for mid-Norfolk, Freeman has served as the minister for Life Science since 2014, a role which was said to be the first of its kind anywhere in the world, focusing directly on the pharmaceutical, biotech, med tech and digital health sectors.

But after almost exactly two years, Freeman is to move on and it now looks likely that the groundbreaking role will be scrapped, with responsibility returning to new ministerial appointments in the Department of Health (DH) and in the Department of Business, Innovation and Skills (BIS).

Freeman’s new role was announced at the weekend, and the reshuffle at the DH and BIS is still being finalised.

The news is undoubtedly a disappointment for the pharma and biotech sectors, who looked to Freeman to help champion the sector – his most notable achievement being the commissioning of the Accelerated Access Review (AAR), and end-to-end review aimed at boosting the life science and the NHS.

Freeman, a one-time biotech venture capital fund manager, won many friends and admirers during his time as Life Science minister, but wasn’t in the post long enough to see his plans come to fruition.

This includes the AAR, which has been repeatedly delayed, including by the EU referendum and its aftermath, but is now pencilled in for a launch in September.  Another top priority for Freeman was the roll-out of electronic health records on the NHS – but concerns about privacy and consent have seen the care.data scheme scrapped.

One of Freeman’s last acts in the Life science post was to convene a special UK EU steering group to help the life sciences sector through the UK’s exit from the European Union, which is likely to take at 18 months.

The pharma and biotech sectors had campaigned to remain in the EU, and will now want reassurances that their businesses won’t suffer in the long term from the many potential consequences.

Despite being an energetic ‘Remain’ supporter before the referendum, Freeman has since expressed confidence that the UK can exploit many new opportunities from Brexit. Pharma leaders seem happy to contribute to this positive approach, but will first seek reassurances on fundamentals such as freedom of movement of goods and people, as well as UK-specific questions such as funding and market access for medicines.

David Mowat, MP for Warrington South and Nicola Blackwood, MP for Oxford West & Abingdon and chair of the science and technology select committee, have been named as part of a new ministerial team at the Department of Health.

A tweet by George Freeman earlier today suggested that Mowat and Blackwood would take over his brief for genomics, digital health and the AAR, however no official announcement on this has been made yet.

However it looks likely that no-one will take on his cross-departmental role, and the Life Sciences minister portfolio will be divided up.

Commenting on the news of his departure, UK pharma industry association the ABPI said Freeman had been “a dedicated and experienced Minister advancing the agenda” for the UK life sciences sector.

At a time of great uncertainty for the pharmaceutical industry we are eager to see who will take up the responsibility of progressing the good work that Freeman has started.  This should include the continuation of the UK-EU Life Sciences Transition Steering Group to address regulatory and funding issues facing the pharmaceutical and biotech sectors following Britain’s decision to leave the European Union, as well as initiatives including the much anticipated Accelerated Access Review which was set up to make the UK the best place in the world to discover, develop and deliver innovative medicines to patients.”

 

Philip Dunne appointed to health department

19 July, Dispensing Doctors Association, Ailsa Colquhoun

 

Philip Dunne has been announced as a health minister in the cabinet reshuffle following the appointment of Theresa May as prime minister.

The Ludlow MP moves from a four-year stint in the defence department, and this is believed to be his first appointment in health. It is not yet clear whether his portfolio will include pharmaceutical services.

During his time in politics, Mr Dunne has formerly chaired the APPG on rural services, and during this time he discussed issues such as the implications of national funding formulae for rural health.

He also shows awareness of dispensing doctor issues: in 2007 as a member of the Public Accounts Committee he contributed to a report on prescribing costs in primary care in which he pointed out: “patients in rural areas tend to have a closer relationship with their GP and are perhaps more resistant to change than patients in an urban area”.

He also noted that GPs that also operate as dispensing practices “generate quite a significant proportion of their remuneration from dispensing activities” and asked: “Is there not an inherent conflict for them in seeking to reduce the cost of prescribing with their own remuneration?”

Professor Colin-Thome´ responded: “Dispensing doctors provide an excellent service where pharmacies are not available. In fairness, the average costs and prescribing patterns were very similar, and there were only one or two small examples in which that was not the case.”

Mr Dunne was also involved in discussions relating to the 2008 white paper consultation on pharmacy services, and asked whether dispensing GPs will continue to be allowed to dispense.

Mr Dunne is a lifelong Conservative and has campaigned at elections since 1974. He was brought up on the family farm near Ludlow, for which he has had responsibility since 1987. He lives near Ludlow, which he has regarded as his home town all his life.

He joins health secretary Jeremy Hunt, who has survived the reshuffle.

HDA Media And Political Bulletin – 19 July 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?